Cargando…
Screening of Big Pharma’s Library against Various in-house Biological Targets
Open innovation initiatives provide opportunities for collaboration and sharing of knowledge and experience between industry, academia, and government institutions. Through open innovation, Merck is offering a Mini Library of 80 carefully selected compounds from previous research and development pro...
Autores principales: | Knez, Damijan, Gobec, Stanislav, Hrast, Martina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320114/ https://www.ncbi.nlm.nih.gov/pubmed/35889355 http://dx.doi.org/10.3390/molecules27144484 |
Ejemplares similares
-
Fragment-Sized
Thiazoles in Fragment-Based Drug Discovery
Campaigns: Friend or Foe?
por: Proj, Matic, et al.
Publicado: (2022) -
Big Pharma (The Play)
por: Bero, Lisa
Publicado: (2007) -
Application of the N-Dibenzyl Protective Group in the Preparation of β-Lactam Pseudopeptides
por: Frlan, Rok, et al.
Publicado: (2019) -
Inhibition of MurA
Enzyme from Escherichia
coli by Flavonoids and Their Synthetic Analogues
por: Frlan, Rok, et al.
Publicado: (2023) -
Next-Generation Heterocyclic Electrophiles as Small-Molecule Covalent MurA Inhibitors
por: Ábrányi-Balogh, Péter, et al.
Publicado: (2022)